Expressions and clinical significances of MAGE-A9, MAGE-A11 and Ki67 in laryngeal squamous cell carcinoma
10.3872/j.issn.1007-385x.2019.12.010
- VernacularTitle:MAGE-A9、 、MAGE-A11 和 Ki67 在喉鳞状细胞癌组织中的表达及其 临床意义
- Author:
LIU Shenghui
1
,
2
,
3
;
ZHAO Yan
4
;
XU Yuru
2
,
3
,
5
;
SANG Meixiang
3
,
6
;
ZHAO Ruili
4
;
GU Lina
7
;
SHAN Baoen
3
,
6
Author Information
1. (a. Department of Otolaryngology
2. b. Department of Research Center
3. c. Tumor Research Institute, Fourth Hospital of Hebei Medical University
4. a. Department of Otolaryngology, Fourth Hospital of Hebei Medical University
5. a. Department of Otolaryngology
6. b. Department of Research Center
7. b. Department of Research Center， Fourth Hospital of Hebei Medical University
- Publication Type:Journal Article
- Keywords:
laryngeal squamous cell carcinoma;
melanoma antigen-A9(MAGE-A9);
melanoma antigen-A11(MAGE-A11);
Ki67;
prognosis
- From:
Chinese Journal of Cancer Biotherapy
2019;26(12):1356-1362
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the expressions of melanoma antigen (MAGE) -A9, -A11 and Ki67 in laryngeal squamous cell carcinoma (LSCC) tissues, and to analyze their correlation with clinicopathological features and the prognosisof LSCC patients. Methods: A total of 73 pairs of LSCC tissuesand corresponding para-cancerous tissues resected from LSCC patients, who were treated at the Fourth Hospital of Hebei Medical University from 2012 to 2014,were collected for this study. At the same time, testicular tissues from 3 patients with prostate cancer after castration were selected as positive control. The protein expressions of MAGE-A9, MAGE-A11 and Ki67 in LSCC tissues and its para-cancerous tissues were detected by immunohistochemistry. Results: The expression rates of MAGEA9, MAGE-A11 protein and Ki67 in LSCC tissues were 47.94% (35/73), 49.32% (36/73) and 46.58% (34/73) respectively, which were significantly higher than those in para-cancerous tissues. The protein expressions of MAGE-A9 and MAGE-A11 were correlated with clinical stage and lymphatic metastasis of LSCC (P<0.05). The expression of Ki67LI was correlated with tumor size, clinical stage and lymphatic metastasis of LSCC (P<0.05). The correlation analysis showed that the expressions of MAGE-A9 and MAGE-A11 were positively correlated with Ki67 (r=0.258, P＝0.027; r=0.672, P=0.001). Kaplan-Meier survival curve analysis showed that the survival rates of patients with high expression of MAGE-A9 protein (P=0.009), MAGE-A11 protein (P=0.031) and Ki67LI (P=0.040) were significantly lower than those with low expressions. And the survival time of patients with both high expressions of MAGE-A9 and Ki67LI (P=0.001) or both high expressions of MAGE-A11 and Ki67 (P=0.001) was significantly shorter than that of patients with low expression (both or single). Univariate and multivariate Cox regression analysis further indicated that MAGE-A9 protein (P=0.028) and MAGE-A11 protein (P=0.042) were independent prognostic factors for overall survival of LSCC patients. Conclusion: MAGE-A9, MAGE-A11 and Ki67 are tumor-associated antigens of LSCC, which can be used as prognostic indicators for LSCC.
- Full text:20191210.pdf
